Skip to main content
SpringerLink
Log in

Cannabinoid-Based Medicines for Neurological Disorders—Clinical Evidence

  • Published:
Molecular Neurobiology Aims and scope Submit manuscript

Abstract

Whereas the cannabis plant has a long history of medicinal use, it is only in recent years that a sufficient understanding of the pharmacology of the main plant constituents has allowed for a better understanding of the most rational therapeutic targets. The distribution of cannabinoid receptors, both within the nervous system and without, and the development of pharmacological tools to investigate their function has lead to a substantial increase in efforts to develop cannabinoids as therapeutic agents. Concomitant with these efforts, the understanding of the pharmacology of plant cannabinoids at receptor and other systems distinct from the cannabinoid receptors suggests that the therapeutic applications of plant-derived cannabinoids (and presumably their synthetic derivatives also) may be diverse. This review aims to discuss the clinical evidence investigating the use of medicines derived, directly or indirectly, from plant cannabinoids with special reference to neurological disorders. Published studies suggest that the oral administration of cannabinoids may not be the preferred route of administration and that plant extracts show greater evidence of efficacy than synthetic compounds. One of these, Sativex® (GW Pharmaceuticals), was approved as a prescription medicine in Canada in 2005 and is currently under regulatory review in the EU.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. O’Shaughnessy WB (1838–40) On the preparations of the Indian hemp, or gunjah (Cannabis indica): their effects on the animal system in health, and their utility in the treatment of tetanus and other convulsive diseases. Trans Med Phys Soc Bengal 421–461

  2. Lazarou J, Pomeranz BM, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279:1200–1205

    Article  PubMed  CAS  Google Scholar 

  3. de Meijer EPM, Bagatta M, Carboni A, Crucitti P, Moliterni VMC, Ranalli P, Mandolino G (2003) The inheritance of chemical phenotype in Cannabis sativa L. Genetics 163:335–346

    PubMed  Google Scholar 

  4. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I et al (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134:845–852

    Article  PubMed  CAS  Google Scholar 

  5. Carrier EJ, Auchampach JA, Hillard CJ (2006) Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. PNAS 103:7895–7900

    Article  PubMed  CAS  Google Scholar 

  6. Sacerdote P, Martucci C, Vaccani A, Bariselli F, Panerai AE, Colombo A, Parolaro D, Massi P (2005) The nonpsychoactive component of marijuana cannabidiol modulates chemotaxis and IL-10 and IL-12 production of murine macrophages both in vivo and in vitro. J Neuroimmunol 159:97–105

    Article  PubMed  CAS  Google Scholar 

  7. Drysdale AJ, Ryan D, Pertwee RG, Platt B (2006) Cannabidiol-induced Ca(2+) elevations in hippocampal cells. Neuropharmacology 50:621–631

    Article  PubMed  CAS  Google Scholar 

  8. Wilkinson JD, Whalley BJ, Baker D, Pryce G, Constanti A, Gibbons S, Williamson EJ (2003) Medicinal cannabis: is THC necessary for all its effects? J Pharm Pharmacol 55:1687–1694

    Article  PubMed  CAS  Google Scholar 

  9. Nicholson AN, Turner C, Stone BM, Robson PJ (2004) Effect of THC and CBD on nocturnal sleep and early morning behaviours in young adults. J Clin Psychopharmacol 24:305–313

    Article  PubMed  CAS  Google Scholar 

  10. Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Holister LE, Gillespie HK (1980) Plasma THC concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 28:409–416

    Article  PubMed  CAS  Google Scholar 

  11. Guy GW, Robson PJ (2003) A Phase 1, open-label, four way crossover study to compare the pharmacokinetic profiles of a single dose of 20mg of a cannabis-based medicine extract (CBME) administered on 3 different areas of the buccal mucosa and to investigate the pharmacokinetics of CBME per oral in healthy male and female volunteers. J Cannabis Ther 3/4:121–152

    Google Scholar 

  12. Perez-Reyes M (1990) Factors that influence the bioavailability of THC. NIDA Res Monogr 99:42–62

    PubMed  CAS  Google Scholar 

  13. Stacquet M, Gantt C, Machin D (1978) Effect of a nitrogen analogue of tetrahydrocannabinol on cancer pain. Clin Pharmacol Ther 23:397–401

    Google Scholar 

  14. Jochimsen PR, Lawton RL, VerSteeg K, Noyes J Jr (1978) Effect of benzopyranoperidine, a Δ-9-THC congener, on pain. Clin Pharmacol Ther 24:223–227

    PubMed  CAS  Google Scholar 

  15. Jain AK, Ryan JR, McMahon G, Smith G (1981) Evaluation of intramuscular levonantrodol and placebo in acute post-operative pain. J Clin Pharmacol 21:320S–326S

    PubMed  CAS  Google Scholar 

  16. Lindstrom P, Lindlom U, Boreus L (1987) Lack of effect of cannabidiol in sustained neuropathia. In: Proceedings of the Marijuana 1987 International Conference on Cannabis, Melbourne, 2nd–4th September

  17. Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U (2003) Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain. A randomized controlled trial. J Am Med Assoc 290:1757–1762

    Article  CAS  Google Scholar 

  18. Salim K, Schneider U, Burstein S, Hoy L, Karst M (2005) Pain measurements and side effect profile of the novel cannabinoid ajulemic acid. Neuropharmacology 48:1164–1171

    Article  PubMed  CAS  Google Scholar 

  19. Noyes R Jr, Brunk SF, Avery DH, Canter A (1975a) The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 18:84–89

    PubMed  Google Scholar 

  20. Noyes R Jr, Brunk SF, Baram DA, Canter A (1975b) Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol 15:139–143

    PubMed  Google Scholar 

  21. Raft D, Gregg J, Ghia J, Harris L (1977) Effects of intravenous tetrahydrocannabinol on experimental and surgical pain. Psychological correlates of the analgesic response. Clin Pharmacol Ther 21:26–33

    PubMed  CAS  Google Scholar 

  22. Buggy DJ, Toogood L, Maric S, Sharpe P, Lambert DG, Rowbotham DJ (2003) Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in post-operative pain. Pain 106:169–172

    Article  PubMed  CAS  Google Scholar 

  23. Naef M, Curatolo M, Petersen-Felix S, Arendt-Nielsen L, Zbinden A, Brenneisen R (2003) The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental conditions. Pain 105:79–88

    Article  PubMed  CAS  Google Scholar 

  24. Maurer M, Henn V, Dittrich a, Hoffmann A (1990) Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. Eur Arch Psychiatry Clin Neurosci 240:1–4

    Article  PubMed  CAS  Google Scholar 

  25. Svendsen KB, Jensen TS, Bach FW (2004) Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. Br Med J 329:253–257

    Article  CAS  Google Scholar 

  26. Woods JR, Williams JG, Tavel M (1989) The two-period crossover design in medical research. Ann Intern Med 110:560–566

    PubMed  CAS  Google Scholar 

  27. Campbell FA, Tramer MR, Carroll D, Reynolds JM, Moore AR, McQuay HJ (2001) Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. Br Med J 323:13–17

    Article  CAS  Google Scholar 

  28. Page SA, Verhoef MJ, Stebbins RA, Metz LM, Levy JC (2003) Cannabis use as described by people with multiple sclerosis. Can J Neurol Sci 30:201–205

    PubMed  CAS  Google Scholar 

  29. Petro DJ, Ellenberger C (1981) Treatment of human spasticity with delta-9-tetrahydrocannabinol. J Clin Pharmacol 21:413S–416S

    PubMed  CAS  Google Scholar 

  30. Clifford DB (1983) Tetrahydrocannabinol for tremor in multiple sclerosis. Ann Neurol 13:669–671

    Article  PubMed  CAS  Google Scholar 

  31. Ungerleider JT, Andrysiak T, Fairbanks L, Ellison GW, Myers LW (1987) Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 7:39–50

    PubMed  CAS  Google Scholar 

  32. Martyn CN, Illis LS, Thom J (1995) Nabilone in the treatment of multiple sclerosis. Lancet 345:579

    Article  PubMed  CAS  Google Scholar 

  33. Hanigan WC, Destree R, Truong XT (1986) The effect of delta-9-THC on human spasticity. Clin Pharmacol Ther 39:198

    Google Scholar 

  34. Hagenbach U, Luz S, Ghafoor N, Grotenhermen F, Brenneisen R, Mader M (2006) The treatment of spasticity with delta-9-tetrahydrocannabinol in persons with spinal cord injury. Spinal Cord (in press)

  35. Sieradzan KA, Fox SH, Hill M, Dick JPR, Crossman AR, Brotchie JM (2001) Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: a pilot study. Neurology 57:2108–2111

    PubMed  CAS  Google Scholar 

  36. Fox SH, Kellett M, Moore AP, Crossman AR, Brothcie JM (2002) Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov Disord 17:145–149

    Article  PubMed  Google Scholar 

  37. Muller-Vahl KR, Schneider U, Koblenz A, Jobges M, Kolbe H, Daldrup T, Emrich HM (2002a) Treatment of Tourette’s syndrome with delta-9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 35:57–61

    Article  PubMed  CAS  Google Scholar 

  38. Muller-Vahl KR, Schneider U, Prevedel H, Theloe K, Kolbe H, Daldrup T, Emrich HM (2003) Delta-9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a six week randomized trial. J Clin Psychiatry 64:459–465

    Article  PubMed  Google Scholar 

  39. Maas AI, Murray G, Henney H 3rd, Kassem N, Legrand V, Mangelus M et al (2006) Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a Phase III randomized, placebo-controlled, clinical trial. Lancet Neurol 5:38–45

    Article  PubMed  CAS  Google Scholar 

  40. McPartland JM, Russo EB (2001) Cannabis and cannabis extracts: greater than the sum of their parts? J Cannabis Ther 1:103–132

    Article  CAS  Google Scholar 

  41. Pertwee RG (2004) The therapeutic potential of cannabidiol. In: di Marzo V (ed) Cannabinoids. Kluwer/Plenum, New York (Chapter 3)

    Google Scholar 

  42. Mechoulam R, Parker LA, Gallily R (2002) Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 42:11S–19S

    PubMed  CAS  Google Scholar 

  43. Long LE, Malone DT, Taylor DA (2006) Cannabidiol reverses MK-801-induced disruption of pre-pulse inhibition in mice. Neuropsychopharmacology 31:795–803

    Article  PubMed  CAS  Google Scholar 

  44. Zuardi AW, Morais SL, Guimaraes FS, Mechoulam R (1995) Antipsychotic effect of cannabidiol. J Clin Psychiatry 56:485–486

    PubMed  CAS  Google Scholar 

  45. Russo E, Guy GW (2006) A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 66:234–246

    Article  PubMed  CAS  Google Scholar 

  46. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG (1982) Action of cannabidiol on the anxiety and other effects produced by delta-9-THC in humans. Psychopharmacology 76:245–250

    Article  PubMed  CAS  Google Scholar 

  47. Nicholson AN, Turner C, Stone BM, Robson PJ (2004) Effect of delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early morning behaviour in young adults. J Clin Psychopharmacol 24:305–313

    Article  PubMed  CAS  Google Scholar 

  48. Perez J (2006) Combined cannabinoid therapy via an oromucosal spray. Med Actual 42:495–503

    CAS  Google Scholar 

  49. Notcutt W, Price M, Miller R, Newport S, Phillips C, Simmons S (2003) Initial experiences with medicinal extracts of cannabis for chronic pain: results of 34 “N of 1” studies. Anaesthesia 59:440–452

    Article  Google Scholar 

  50. Berman JS, Symonds C, Birch R (2004) Efficacy of two cannabis-based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomized controlled trial. Pain 59:440–452

    Google Scholar 

  51. Rog DJ, Nurmikko TJ, Friede T, Young CA (2005) Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 65:812–819

    Article  PubMed  Google Scholar 

  52. Wade DT, Robson P, House H, Makela P, Aram J (2003) A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 17:21–29

    Article  PubMed  Google Scholar 

  53. Wade DT, Makela P, Robson P, House H, Bateman C (2004) Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 10:434–441

    Article  PubMed  CAS  Google Scholar 

  54. Wade DT, Makela PM, House H, Bateman C, Robson P (2006) Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 12:639–645

    Article  PubMed  CAS  Google Scholar 

  55. Collin C, Davies P, Mutoboko I, Ratcliffe S (2007) Randomised controlled trial of cannabis based medicine in spasticity caused by multiple sclerosis. Eur J Neurol (in press)

  56. Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, Fowler CJ (2004) An open label pilot study of cannabis-based extracts for bladder sysfunction in advanced multiple sclerosis. Mult Scler 10:425–433

    Article  PubMed  CAS  Google Scholar 

  57. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A (2003) Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomized placebo-controlled study. Lancet 362:1517–1528

    Article  PubMed  CAS  Google Scholar 

  58. Zajicek JP, Sanders HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM, Nunn AJ, Teare LJ, Fox PJ, Thompson A (2005) Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow-up. J Neurol Neurosurg Psychiatry 76:1664–1669

    Article  PubMed  CAS  Google Scholar 

  59. Killestein J, Hoogervorst ELJ, Reif M, Kalkers NF, van Loenen AC, Staats PGM, Gorter W, Uitdehaag BMJ, Polman CH (2002) Safety, tolerability and efficacy of orally administered cannabinoids in MS. Neurology 58:1404–1407

    PubMed  CAS  Google Scholar 

  60. Vaney C, Heinzel-Gutenbrunner M, Jobin P, Tschopp F, Gattlen B, Hagen U, Schnelle M (2004) Efficacy, safety and tolerability of an oral administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled crossover study. Mult Scler 10:417–424

    Article  PubMed  CAS  Google Scholar 

  61. Carroll CB, Bain PG, Teare BM, Liu X, Joint C, Wroath C, Parkin SG, Fox P, Wright D, Hobart J, Zajicek J (2004) Cannabis for dyskinesia in Parkinson’s disease. A randomized double-blind crossover study. Neurology 63:1245–1250

    PubMed  CAS  Google Scholar 

  62. Thomas A, Stevenson LA, Wease KN, Price MR, Baillie G, Ross RA, Pertwee RG (2005) Evidence that the plant cannabinoid delta-9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. Br J Pharmacol 146:917–926

    Article  PubMed  CAS  Google Scholar 

  63. Guy GW, Robson PJ (2003) A Phase 1, open-label, four way crossover study to compare the pharmacokinetic profiles of a single dose of 20mg of a cannabis-based medicine extract (CBME) administered on 3 different areas of the buccal mucosa and to investigate the pharmacokinetics of CBME per oral in healthy male and female volunteers. J Cannabis Ther 3/4:121–152

    Google Scholar 

  64. Zuardi AW, Cosme RA, Graeff FG, Guimaraes FS (1993) Effects of ipsaspirone and cannabidiol on human experimental anxiety. J Psychopharmacol 104:260–264

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. GW Pharmaceuticals, Porton Down Science Park, Salisbury, Wilts, UK

    Stephen Wright

  2. GW Pharmaceuticals, 1 Cavendish Place, London W1, UK

    Stephen Wright

Authors
  1. Stephen Wright
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephen Wright.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wright, S. Cannabinoid-Based Medicines for Neurological Disorders—Clinical Evidence. Mol Neurobiol 36, 129–136 (2007). https://doi.org/10.1007/s12035-007-0003-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12035-007-0003-4

Keywords

Search

Navigation